The dynamics of measles immunity at birth and following vaccination.
Dizal presents updated PhII PTLC data, plans to file for accelerated approval in the US next year
Dizal said its peripheral T-cell lymphoma drug candidate showed positive efficacy and safety in a Phase II registrational trial, paving the way for a US